BioDelivery Sciences readies BEMA for application; pSivida's Iluvien gets Spanish agency nod;

> AstraZeneca ($AZN) has signed up with U.K.-based materials development company Ceram to develop extended-release versions of AstraZeneca compounds. Ceram's controlled-release technologies use glass, ceramics and powder to deliver individual drugs or drug combinations over extended periods. Press release

> BioDelivery Sciences International ($BDSI) has completed the safety study of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone, known as BNX. According to the company, it's still on track for a midyear new drug application submission. Press release

> Omeros finished its Phase III trial for OMS302, which eases the pain and discomfort of cataract and other lens-replacement surgery. Press release

> Velocity Pharmaceutical Development and EuMederis Pharmaceuticals have joined forces to improve the overall handling of peptides, including their delivery. Report

> The Spanish Agency of Drugs granted marketing authorization to pSivida ($PSDV), a sustained-release drug company, for Iluvien, designed to treat vision impairment associated with chronic diabetic macular edema. Report

> The FDA issued a complete response letter for the NDA of Rytary extended-release capsules by Impax Laboratories ($IPXL). The agency stated that it would require a re-inspection of the company's facility before the NDA can be approved. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.